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Phe Genetic Bases of Cardiomyopathies
ascale Richard, MD, PHD,†§ Eric Villard, PHD, Philippe Charron, MD, PHD,*‡ Richard Isnard, MD*§
aris, France
Cardiomyopathies represent an important cause of cardiovascular morbidity and mortality
due to heart failure, arrhythmias, and sudden death. A majority of hypertrophic cardiomy-
opathies (HCM) and at least 30% of dilated cardiomyopathies (DCM) are familial forms,
with most often an autosomal dominant mode of inheritance. Over the last 15 years, our
knowledge on the genetic bases of these diseases has considerably improved. Cardiomyopa-
thies are characterized by a great genetic heterogeneity at both allelic and non-allelic levels.
Hypertrophic cardiomyopathies are mainly linked to mutations on genes encoding sarcomeric
proteins, and beta myosin heavy chain and myosin binding protein C gene mutations account
for about 80% of genotyped cases. Familial DCM is associated with mutations in genes
encoding sarcomeric proteins but also other proteins of the myocyte, such as cytoskeletal or
nuclear membrane proteins. Due to the genetic heterogeneity and the variable clinical
expressivity of these diseases, the relations between genotype and phenotype remain complex,
but the age of onset, the clinical severity, or associated phenotypes may be, at least in part,
related to the precise gene mutations. Therefore, besides a better understanding of the
molecular basis for cardiac remodeling and heart failure, the genetic analysis of cardiomyop-
athies is going to play an increasing role in the routine management of these patients in the
following years, particularly in HCM. (J Am Coll Cardiol 2006;48:A79–89) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.014American College of Cardiology Foundation
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hhe role of genetic factors in the pathogenesis of cardio-
yopathies has received growing attention during the past
5 years and dramatically changed our understanding of
hese diseases. Cardiomyopathies are defined as diseases of
he myocardium with cardiac dysfunction and can be com-
licated by heart failure, arrhythmias, and sudden death (1).
herefore, they represent an important cause of cardiovas-
ular morbidity and mortality, and a frequent reason for
ardiac transplantation. They are classified into 4 main
istinct entities according to the type of anatomical and
unctional impairment: dilated, hypertrophic, restrictive,
nd arrhythmogenic right ventricular dysplasia, the 2 former
eing the most frequent forms and focused on in this review.
or hypertrophic cardiomyopathy (HCM), increasing rec-
gnition that most cases were familial forms has led to
ttempts for identifying the genetic defect. Since the dis-
overy of the first mutation in the beta-myosin heavy chain
ene in a large French-Canadian family in 1990 (2), a large
umber of mutations on different genes encoding sarco-
eric proteins has been found. The identification of morbid
enes in dilated cardiomyopathy (DCM) is more recent, but
his disease is also characterized by a great genetic hetero-
eneity, which makes the genetic approach of the cardio-
yopathies complex.
Besides the improvement of our knowledge of the mo-
ecular mechanisms of these diseases, the genetic diagnosis
s beginning to have some important clinical implications in
he routine management of the patients.
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ypertrophic cardiomyopathy is a myocardial disease de-
ned by an unexplained left ventricular hypertrophy (LVH),
sually asymmetrical and involving the interventricular sep-
um. This definition implies that a detectable cause of
ypertrophy such as hypertension or amyloidosis must be
xcluded. This LVH is generally associated with normal
ystolic function, abnormal diastolic function, and is respon-
ible for a systolic dynamic obstruction of the left ventricular
utflow tract in about 25%. Histopathological features of
CM are myocyte hypertrophy with myocardial disarray
nd increased interstitial fibrosis (3). Several echocardio-
raphic studies on cohorts of adults from various ages and
aces have reported an estimated prevalence of unexplained
ypertrophied non-dilated left ventricle (wall thickness 15
m), compatible with the diagnosis of HCM, of about 1 of
00 (4,5). Hypertrophic cardiomyopathy is a familial disease
n at least 50% of cases, with an autosomal dominant mode
f inheritance. The penetrance of the disease is nearly
omplete but dependent on age and gender.
The clinical pattern is highly heterogenous: many pa-
ients have no symptoms during their whole life, but, in
ome cases, HCM may lead to severe symptoms such as
yncope or dyspnea, to sudden death, or congestive heart
ailure, and it remains the most prevalent cause of sudden
eath in athletes during exercise (3).
AUSAL GENES AND MUTATIONS
enes. The genetic aspect of HCM is characterized by a
igh heterogeneity both at allelic and non-allelic level. Thedentification of 13 disease genes encoding sarcomeric
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Genetic Bases of Cardiomyopathies November 7, 2006:A79–89roteins has led to the definition of primary HCM as a
isease of the sarcomere. Four genes code for proteins of the
hick filament (MYH7- myosin heavy chain, MYH6-
yosin heavy chain, MYL2 regulatory myosin light chain,
YL3 essential myosin light chain); 5 genes code for the
hin filament structure (ACTC cardiac actin, TPM1-
ropomyosin, TNNT2 cardiac troponin T, TNNI3 cardiac
roponin I, TNNC1 cardiac troponin C); 2 genes code for
ssembly proteins (MYBPC3 cardiac myosin binding pro-
ein C and TTN titin); 2 genes code for proteins of the Z
and (TCAP telethonin, CRP3 muscle LIM protein) (Table
). In addition, rare mutations in genes coding for associ-
ted proteins such as vinculin and metavinculin have been
eported (6).
istribution of genes. The distribution of the disease
enes by identification of pathogenic mutations was exten-
ively determined in several Caucasian populations. In the
xperience of the French population, the causal mutation
as identified in 61% of HCM patients using single-strand
onformation polymorphism as detection method (7), sug-
esting that a potential higher rate could be found with a
ore sensitive technology. In all cohorts, MYBPC3 and
YH7 were the most common genes responsible for the
isease, each of them being involved in 30% to 40% of
able 1. Sarcomeric Genes and Mutations Involved in
ypertrophic Cardiomyopathy
HCM Gene Symbol
Chromosome
Locus Mutations
eta-myosin
heavy chain
MYH7 14q12 194*
yosin-binding
protein C
MYBPC3 11p11.2 149†
roponin T TNNT2 1q32 31‡
roponin I TNNI3 19q13.4 27§
lpha-tropomyosin TPM1 15q22.1 11
egulatory myosin
light chain
MYL2 12q24.3 10
ssential myosin
light chain
MYL3 3p21 5
ctin ACTC 15q14 6
ardiac troponin C TNNC1 3p 1
itin TTN 2q24.3 2
lpha-myosin
heavy chain
MYH6 14q12 1
uscle LIM
protein
CRP3 11p15.1 1
elethonin TCAP 17q12 1
genetics.med.harvard.edu/seidman/cg3/muts/MYH7_mutations_TOC.html.
genetics.med.harvard.edu/seidman/cg3/muts/MYBPC3_mutations_TOC.html.
Abbreviations and Acronyms
ATP  adenosine triphosphate
DCM dilated cardiomyopathy
HCM hypertrophic cardiomyopathy
LVH  left ventricular hypertrophyT
genetics.med.harvard.edu/seidman/cg3/muts/TNNT2_mutations_TOC.html.
genetics.med.harvard.edu/seidman/cg3/muts/TNNI3_mutations_TOC.html.enotyped index patients. TNNT2, TNNI3, TPM1, ACTC,
YL2, and MYL3 are involved in 1% to 5% of cases (7–11).
he other genes are reported only in few cases not allowing
o-segregation analysis (12,13). Nowadays in our experience
f a clinical molecular diagnostic laboratory, the mutations
etection rate reaches 70% in index patients with HCM. In
ddition, a recent study showed that the morphology of the
eptum hypertrophy could predict the yield of mutations
ound in the sarcomeric genes (14). In the remaining
atients, the lack of identified disease-causing mutation may
e due to other causes of LVH, lack of sensitivity of
creening technologies, mutations in not yet explored in-
ronic or regulation sequences of genes, or still unknown
enes.
utations. Extensive analysis of these genes revealed an
mportant non-allelic heterogeneity by the identification of
ore than 400 mutations. The spectrum of pathogenic
utations is different between the 2 major genes MYH7 and
YBPC3. In MYH7, nearly 200 mutations are described.
mong them, 70% are located in the globular head and
eck domains of the protein coding regions, and 30% are
ocated in the rod domain. These mutations are almost
xclusively missense (96%), but several codon deletions not
isrupting the reading frame have also been found, all
ocated in the flexible domain of the protein between the
lobular head and the rod domain (del Lys847, del Glu883,
el Glu927, del Glu930). In MYBPC3, there are about 150
dentified mutations, located along the whole gene: 70% of
hem are non-sense mutations leading to a putative null
llele (termination codon, splice site mutations, small dele-
ions, or insertions disrupting the reading frame), whereas
0% of them are missense. In the TNNT2 and MYL2 genes,
he identified mutations are located all along the coding
equence, but in TNNI3, all mutations identified so far
xcept 1 are located in exon 7 and 8 encoding for the
-terminal domain of the protein. The only deletion found
s at the end of exon 8 encompassing the stop codon (15).
inally, in our experience of a large scale mutation identi-
cation study, the rate of unknown mutations found (never
dentified before but not “de novo” mutations) in 1 of the 2
enes MYH7 and MYBPC3 is between 60% and 80%
epending on the population and the number of index
atients tested. Thus, most mutations in HCM are private
i.e., only related to a single family and very few mutations
re found in more than 1 family). However, in each gene,
everal residues have been described to be hot spots for
utations as Arg403, Arg453, Arg663, Gly741, Arg719,
nd Asp778 in the MYH7 gene, and Arg502, and the splice
cceptor site variant IVS20-2: a  g in the MYBPC3 gene,
odon Arg92 in TNNT2, or codon Arg58 in MYL2. The
act that mutations are private to each family have implica-
ions for the molecular diagnosis, in a sense that it is
ecessary to sequence the entire gene at least for the most
ommonly involved ones (MYH7, MYBPC3, TNNT2,
NNI3, TPM1, MYL2, MYL3, and ACTC).
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November 7, 2006:A79–89 Genetic Bases of CardiomyopathiesMPACT OF GENETICS ON THE
NDERSTANDING OF THE DISEASE
olecular pathogenesis. The mechanisms by which a
arcomere single mutation leads to HCM is far from being
otally understood (16–19). The sarcomere is a complex
tructure with an exact stoichiometry and multiple sites of
nteraction between proteins (17,18), and the mechanism of
ardiac contraction is also complex. After depolarization,
he intracellular calcium binds to the troponin complex; this
llows the myosin head to bind to actin and, after adenosine
riphosphate (ATP) hydrolysis, to be displaced along the
hin filament. Thin and thick filaments slide past one
nother, driving sarcomere shortening and muscle contrac-
ion. The role of cardiac binding myosin protein C remains
oorly understood; it may participate in the thick filament
ssembly by binding to myosin heavy chain and titin, and
ave some regulatory function (20).
Most of the heterozygous mutations are missense, espe-
ially in the MYH7 gene, and lead to a mutant protein with
replacement of an amino acid by another one; this mutant
rotein has been shown to incorporate into the sarcomere,
nd is supposed to interfere with the wild-type protein,
cting as poison polypeptide with a dominant negative effect
21). The result of this incorporation is an abnormal
unction and/or assembly of the sarcomere with myofibrillar
isarray. This hypothesis is supported by a variety of results
btained by in vitro studies, engineered animal models, and
are in vivo studies from explanted hearts from patients with
CM (16,17).
On the other hand, especially in the MYBPC3 gene but
lso in other genes, the identification of null mutations
frame-shift and non-sense) have suggested a putative
echanism of haploinsufficiency by the production of an
nstable transcript and/or a truncated protein unable to
ncorporate into the sarcomere. This mechanism was not
onfirmed in studies related to MYBPC3 and TNNT2 genes
22), in which a dominant negative action was even shown
23). However, it has been recently shown in heterozygous
YBPC3 null mice that this mutant protein was undetect-
ble in the myocardial tissue, and therefore could lead to an
ltered stoichiometry of sarcomere proteins (24).
The generation of engineered animal models of human
utation has allowed a more accurate evaluation of the
rocesses leading from the gene defect to the HCM
henotype (25–28). However, the experimental studies
erformed either in vitro or in animal models have shown
iscrepancies regarding the impact of mutations on the
unction, not necessarily related to the gene or the mutation.
n some models, Ca(2) sensitivity and actin-activated
TPase activity were reduced, resulting in a decrease of
cto-myosin interactions, and finally a decrease in myocyte
ontractility (29,30). The impaired myocyte contractility is
upposed to activate the release of stress-related signaling
inases and trophic factors, which stimulate myocyte hyper-
rophy. This chronology is supported by the fact that bunctional impairment (diastolic abnormalities) precedes the
evelopment of hypertrophy (31).
However, this concept may be misleading because differ-
nt results have also been observed in many other models,
hich are associated with enhanced ATPase activity in
yosin and enhanced actomyosin interaction, leading to an
ncrease of the force generation and the cardiomyocyte
ontractility (21,32–34). The consequence of this gain of
unction is an increased work and energy consumption. In
ddition, the co-existence of mutant and wild-type proteins
ithin the sarcomere may result in uncoordinated contrac-
ion. Finally, this process may lead to energy depletion,
yocyte death, and replacement fibrosis (18). The hypothesis
hat energy depletion underlies HCM is also supported by the
CM-like phenotype found with mutations in mitochondrial
NA mutations or PRKAG2 gene mutations (35).
Additionally, it has also been suggested that calcium
athways could play a critical role in the myocyte hypertro-
hy process (36). Other emerging hypothesis have been
ecently raised: in Drosophila, the overexpression of human
utant cMyBP-C is associated with a down-regulation of
everal genes encoding sarcomeric proteins and a change in
he expression of genes involved in several metabolic path-
ays, compatible with the energy depletion hypothesis (37).
sing an adenovirus-based approach in neonatal rat cardio-
yocytes, the expression of human mutant cMyBP-C is
ecreased, and the truncated proteins are preferentially
egraded by the ubiquitin-proteasome system, whose pro-
eolytic capacity for other substrates may be competitively
mpaired and may result in hypertrophy (38).
Taken together, all these observations and findings in
nimal models revealed the complexity and the probable
nvolvement of multiple mechanisms implicating multipro-
ein complexes in the pathophysiology of HCM.
nheritance and penetrance. Most of the patients are
eterozygous for the mutation, which segregates as an
utosomal dominant trait, the mutation being transmitted
y one of the parents. However, some de novo mutations
ave also been reported (39,40). In some cases (3% to 5%),
different mutations may be present in a same individual,
ost often in MYH7 and MYBPC3 leading either to
ompound heterozygous patients (2 heteroallelic mutations
n the same gene), double heterozygous patients (2 het-
rozygous mutations in 2 different genes), or homozygous
atients (same mutation on the 2 alleles of the same gene)
7,41,42). This finding must be taken into account in the
ontext of the genetic counseling.
Molecular studies have shown that 20% to 30% of adult
atients were healthy carriers (i.e., carried the mutation but
id not express the disease at time of inquest). However,
rospective studies are needed in order to confirm whether
r not the “healthy carriers” are going to develop the disease
ater.
enotype-phenotype relations. The degree of hypertro-
hy, the age of onset, and the severity of the symptoms have
een shown to be, at least in part, related to the precise gene
m
p
u
h
i
d
P
(
a
V
o
s
h
a
d
n
t
M
c
l
b
t
d
H
c
d
t
a
e
g
(
c
m
g
r
s
w
r
p
d
z
o
b
p
H
m
P
O
g
t
r
c
b
s
t
n
c
i
o
M
t
f
b
T
2
g
e
w
H
t
n
f
a
m
d
c
p
c
fl
m
(
o
(
p
h
m
d
s
e
y
p
o
d
c
(
c
f
o
v
a
d
i
g
w
e
A82 Richard et al. JACC Vol. 48, No. 9 Suppl A
Genetic Bases of Cardiomyopathies November 7, 2006:A79–89utations, but these results remain to be confirmed in large
rospective studies. For example, TNNT2 mutations are
sually associated with a severe phenotype that is relatively
omogenous among mutations and characterized by a high
ncidence of sudden death, especially in young patients
espite a mild degree of hypertrophy (43). However, the
he110Ile mutation is associated with a favorable outcome
44). In MYH7 mutations, the phenotype varies consider-
bly according to the mutations, some mutations, such as
al606Met being associated with a benign phenotype, when
thers such as Arg403Gln are associated with reduced
urvival, complete penetrance in adults, and high degree of
ypertrophy (45,46).
The reason for this variability is not clearly understood
nd does not seem to be related to the affected functional
omain. It has been suggested that it could be related to the
et electrical charge of the protein. However, many excep-
ions have been subsequently described. Compared with
YH7 mutations, mutations on MYBPC3 are usually asso-
iated with a delayed onset, an incomplete penetrance, a
ower degree of hypertrophy, and a better survival (47,48),
ut another study has reported undistinguishable pheno-
ypes between these 2 genes (8). Finally, patients with
ouble mutations generally exhibit a more severe form of
CM than patients with single gene defects; this is espe-
ially true for homozygous patients (7,41,49,50).
There is also a great variability in the expression of the
isease even among individuals of the same family who carry
he same mutation. It is, therefore, evident that other factors
re likely to modulate the phenotype. These factors can be
nvironmental; for example, it has been shown that mono-
enic twins could have very different degree of hypertrophy
51), and it can be speculated that exercise or blood pressure
ould play a role in the hypertrophic response to a single
ajor gene mutation. Other factors can be related to the
enetic background of the individual (modifier genes); the
ole of modifier genes has been supported by experimental
tudies in transgenic mice and also in human beings, in
hom several genetic polymorphisms mainly related to the
enin-angiotensin-aldosterone system have been shown to
lay a role. The most commonly implicated is the insertion/
eletion polymorphism of the angiotensin-converting en-
yme, which has been shown to be associated with the risk
f sudden cardiac death and the severity of LVH (52–57),
ut endothelin (54) and angiotensin II type 2 receptor (58)
olymorphisms have also been reported as modifier genes.
owever, the intrinsic variability related to causal genes
akes the search for modifier genes complicated.
RACTICAL IMPLICATIONS FOR THE CLINICIAN
ne key issue for the clinician is how to use these new
enetic tools for the routine care of patients (59). Until now,
hese molecular analyses have been confined in few
esearch-oriented laboratories because it is a time-
onsuming and expensive process, and it is not yet reim- bursed by the health care systems. However, there are now
everal potential clinical applications that deserve the rou-
ine sequencing of at least major genes.
Due to the large genetic heterogeneity and the fact that
o single mutation predominates within each of the
ausal genes, the molecular strategy for an index patient
n a given family should be based on a direct sequencing
f the 2 most frequently involved genes, MYH7 and
YBPC3, which are each responsible for at least 40% of
he already known mutations (Fig. 1). If no mutation is
ound in these 2 genes, this first step should be followed
y the sequencing of TNNT2, TNNI3, MYL2, MYL3,
PM1, and ACTC, which allows identification of 10% to
0% more mutations (7,60). The screening of the other
enes cannot be recommended in routine care. Although
xtensive molecular analyses, a mutation is not found
ith current tools in up to 30% to 50% of families with
CM. Obviously this negative finding does not exclude
he diagnosis of HCM but only means that an additional
ot yet described gene is probably involved in the given
amily. Another explanation is the possibility of an
lternative pathology that may mimic HCM such as
etabolic cardiomyopathies; Anderson-Fabry disease
ue to mutations in the gene of -galactosidase should be
onsidered in all cases of unexplained LVH, as it is a
otentially treatable cause (61); unexplained LVH asso-
iated with Wolff-Parkinson-White syndrome may re-
ect mutations in the 2 regulatory subunit of adenosine
onophosphate–activated protein kinase (PRKAG2)
62); finally, X-linked HCM can be related to mutations
f lysosome-associated membrane protein (LAMP2) gene
Danon’s disease) (63).
Once a mutation has been identified in an index
atient, genetic testing can be proposed to the apparently
ealthy relatives, in order to know if they carry the
utations and if they have a risk of developing the
isease later on (51,64); the identification of a mutation
hould lead to a more careful clinical follow-up (for
xample, electrocardiogram and echocardiography every
ear) and to exclude competitive sports or sportive
rofessional carriers. On the other hand, in the absence
f mutation, the relative will be reassured for the risk of
eveloping the disease and of transmitting it to his
hildren, and no more cardiologic follow-up is needed
Fig. 1). However, the potential advantages of the pre-
linical genetic diagnosis may be counterbalanced by the
act that there is no preventive treatment for delaying the
nset of the disease; the clinical expression is highly
ariable and the disclosure of mutation can induce
dverse psychological consequences, especially in chil-
ren. Therefore, this process must be discussed with the
ndividuals using the multidisciplinary approach of a
enetic counseling (64). Similarly, the prenatal diagnosis,
hich is theoretically possible, raises much more complex
thical, psychological, and medical problems, and should
e restricted to very few selected cases.
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November 7, 2006:A79–89 Genetic Bases of CardiomyopathiesIn other situations, molecular analysis can help to distin-
uish other causes of hypertrophy from HCM; for instance,
n athletes with mild cardiac hypertrophy, it is crucial to
ifferentiate a physiological hypertrophy in response to
xercise from an early stage of HCM, and in some uncertain
orms, the finding of an HCM mutation may have a major
mplication regarding the continuation of his competitive
areer. However, on the other hand, the absence of HCM
utation cannot exclude the diagnosis.
Finally, genetic testing may sometimes help the clinician to
etter stratify the risk of sudden death in patients with HCM.
esides clinical risk factors (familial sudden death, syncope,
revious sudden death, severe LVH, and abnormal blood
ressure response to exercise), the presence of a malignant
utation (i.e., TNNT2 mutation) can, on a case-by-case basis,
nfluence the decision for the implantation of a cardiac defi-
rillator. However, this strategy is not validated and applies
nly to mutations, which have been clearly associated with a
igure 1. Proposals of molecular diagnosis in patients with hypertrophic ca
entricular; SD  sudden death.igh risk of death in several large families. hCM
ilated cardiomyopathy is the most prevalent cause of conges-
ive heart failure in young patients, with an estimated preva-
ence of 36 of 100,000 in the U.S., and also an important cause
f cardiac transplantation (65). It is characterized by cardiac
hamber enlargement, thin wall thickness, and depressed left
entricular systolic function. Histologic findings are non-
pecific including myocyte loss and interstitial fibrosis (66).
amilial cases of DCM were initially considered as quite rare.
owever, recent studies with a systematic and careful screen-
ng of relatives have shown that up to 35% of patients with
CM had a familial disease (30,67–69). In these families, the
attern of inheritance is variable, including autosomal domi-
ant, autosomal recessive, X-linked, or mitochondrial mode of
ransmission. However, autosomal dominant pattern is the
ost frequent mode of inheritance. The penetrance of DCM
s variable and age-related (70). The phenotype is also highly
yopathy (HCM). ICD implantable cardioverter-defibrillator; LV lefteterogeneous, in terms of functional severity, degree of cardiac
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Genetic Bases of Cardiomyopathies November 7, 2006:A79–89ilatation, and impairment of systolic function, and also
ecause the myocardial disease may be isolated, or associated
ith cardiac conduction disease or muscular dystrophy (69).
enes and mutations. Since the identification of the first
utation responsible for autosomal dominant DCM in the
ene encoding the sarcomeric protein alpha-actin in 1998
71), many studies have been conducted to identify the
olecular basis of familial, monogenic forms of DCM.
resently, at least 15 different causal genes have been
dentified with variable individual prevalence ranging from
1% to 10% (72–74). These genes are related not only to
arcomeric proteins but also to proteins of the nuclear
embrane, lamin A and lamin C (lamin A/C) (75),
ytoskeletal (desmin, dystrophin, and dystrophin-
arcoglycan complex) (76,77), and phospholamban (78)
Table 2). Moreover, 7 loci genetically linked to DCM have
een reported but without gene identification. Interestingly,
areful examination of these linkage regions fails to pinpoint
trong candidate genes according to standard criteria such as
ardiac restricted expression or function related to known
eart physiology. Thus, there are some other, yet unknown,
enes responsible for familial DCM.
unctional consequences of mutations. The very large
enetic and phenotypic heterogeneity observed in DCM
uggests several different mechanisms conducting from mu-
ations to disease. To date, DCM-responsible genes iden-
ified are all expressed in the cardiomyocytes. Encoded
roteins are involved in many different metabolic or struc-
ural functions in the cardiac cell, and numerous pathophys-
ological hypotheses have been formulated in order to link
he mutations to the disease process (19). First, mutations in
arcomeric proteins are believed to be responsible for a
eficit in force production. Mutations in contractile appa-
Table 2. Main Genes Involved in Monogenic
DCM Gene Locus
Beta-myosin heavy chain 14q12
Actin 15q14
Troponin T 1q32
Alpha-tropomyosin 15q22.1
Titin 2q24.3
Muscle LIM protein 11p15.1
Telethonin 17q12
Dystrophin Xp21
Desmin 2q35
Metavinculin 10q22.1-10q23
Beta-sarcoglycan 4q12
Delta-sarcoglycan 5q33
Taffazin Xq28
Lamin A/C 1q21
Phospholamban 6q22.1atus proteins such as beta myosin heavy chain, cardiac clpha-actin, and troponin-tropomyosin complex could lead
o DCM. Force production impairment due to reduced
ctomyosin interaction or impaired ATP utilization, for
yosin head mutations, and decreased Ca2 sensitivity due
o mutations in the troponin genes have been postulated and
artially confirmed by experimental results (72,79,80).
owever, given the absence of regional clustering of muta-
ions in specialized domains of encoded proteins, multiple
athways responsible for disease onset can be discussed for
utations taking place in the same gene. For instance, it is
nlikely that mutations in the tail domain of beta myosin
eavy chain could play a role in force generation but they
ould more probably be involved in the structural conserva-
ion of the thick filament integrity and resistance to stretch.
utations of sarcomeric structural components, in gene
ncoding the sarcomeric backbone titin and in components
f the Z-line (ZASP/Cypher and alpha-actinin 2) have also
een reported (81–83). There is no clear evidence of the
isease mechanisms associated with mutations in these
enes. An interesting possibility could be an alteration of
oth stretch sensing and downstream signaling to the
ucleus leading to cardiac remodeling and DCM. This has
een demonstrated in muscle LIM protein knock-out mice,
model of human DCM, in which stretch sensing is
mpaired and leads to heart dilation and failure (84). The
ardiac mechanical stretch sensor machinery involves a Z
isc complex that is defective in a subset of human DCM.
Interestingly, even if sarcomere protein gene mutations
eading to DCM are distinct from HCM-causing muta-
ions, they may affect very close amino acid residues (73).
Another probable mechanism could be a deficit in force
ransmission from cell to cell leading to heart dilatation in
ene mutations of proteins involving intermediate filament,
s of Dilated Cardiomyopathy
Inheritance Associated Phenotype
utosomal dom. —
Id —
Id —
Id —
Id —
Id —
Id —
X linked Skeletal myopathy
utosomal dom. Possible skeletal myopathy
Id —
Id Skeletal myopathy
Id Skeletal myopathy
X linked Barth syndrome
Left ventricular non-
compaction
utosomal dom. Skeletal myopathy
Conduction disorders
Atrial fibrillation
Emery-Dreifuss muscular
dystrophy
utosomal dom. —Form
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November 7, 2006:A79–89 Genetic Bases of Cardiomyopathiesarcomere like desmin, dystrophin-sarcoglycan complex, or
etavinculin (76,85,86). This functional hypothesis results
ainly from the known function of the proteins and a few
xperimental results. For instance, metavinculin, the
ardiac-specific isoforms of vinculin, and desmin are known
o participate in sarcomere anchoring to intercalated Z
isks, to the plasma membrane, and, for desmin, to the
ucleus. Mutated proteins might result in an impairment of
he transduction of mechanic forces through the cellular
rchitecture and to adjacent cells. An intriguing question
oncerns DCM due to LMNA mutations, encoding lamin
/C protein, which is organized as a network, located at the
nner nuclear membrane and involved in membrane struc-
ure integrity and chromatin interaction. LMNA mutations
re associated with a very wide number of phenotypically
nrelated syndromes including DCM associated with con-
uction disorders. There is no definite explanation on
nderlying mechanisms for cardiac or non-cardiac disorders
esulting from LMNA mutations. However, LMNA knock-
ut in mice suggests that a lack in lamin protein results in a
oss of desmin intermediate filament anchoring to the
ucleus; this might induce a decrease in cytoskeletal tension
nd subsequent defect in force transmission (87).
More recently, a role for Ca cycling regulation has been
emonstrated in a family presenting with DCM and a
utation in the highly conserved phospholamban protein,
he regulator of the sarcoplasmic endoplasmic reticulum
alcium ATPase (SERCA)2a calcium pump of the endo-
lasmic reticulum. The Arg9Cys substitution induced by
he heterozygous mutation is, in transgenic mice over-
xpressing the mutant phospholamban, responsible for
hronic inhibition of the SERCA function, depressed con-
ractility and, ultimately, heart dilation (78).
enotype-phenotype relations. Some gene mutations are
ssociated with specific phenotype; for example, mutations
n genes encoding intermediate filaments or cytoskeletal
roteins (dystrophin, dystrophin sarcoglycan complex,
esmin) can be responsible for DCM associated with
keletal myopathy or increased plasma creatine kinase
76,77). LMNA mutations can cause DCM with conduc-
ion disorders (atrioventricular block of different degree,
inus node dysfunction), atrial fibrillation, and skeletal
yopathy (Table 2) (66,67,75,88). Due to the fact that most
Table 3. Genes of Susceptibility in Non-Mono
Gene Polymorph
PAF acetyl hydrolase G994T
Superoxyde dismutase Val16Ala
HLA-DR DRB1*140
Endothelin receptor A exon 8 C/T
Nebulette actin-binding protein Asn654Lys
TGF-beta1 Leu10Pro
2C AR Del322-32
HLA-DQ DQA1*050
AR  adrenergic receptor; CI  confidence interval; HLA 
 transforming growth factor.utations described so far are private or observed in few mamilies, little information is available on genotype-
henotype relationship for other mutations; however, it has
een suggested that MYH7 mutations were associated with
ater onset, incomplete penetrance, and delayed major car-
iac events compared with troponin mutations (73).
on-monogenic forms of DCM. Unlike HCM, most
CM forms cannot be assigned to single gene defects. In
hese forms, environmental, viral, or immunological factors
re likely to play a key role in the pathogenesis of the
isease. However, even in these multifactorial forms, it can
e hypothesized that genetic factors could influence either
he development or the evolution of the disease. Some
enes, susceptibility genes, have been shown usually through
ase-control studies to be associated with an increased risk
f developing a DCM (Table 3). Other genes such as genes
elated to the renin-angiotensin system or the adrenorecep-
ors were reported as modifier genes defined as genetic
actors, which may modulate the phenotype of a disease
sually in terms of severity and prognosis (Table 4). In
ddition, very few data are reported about pharmacogenetic
nteractions. In a retrospective study, interaction between
eta-blockers and the insertion/deletion angiotensin-
onverting enzyme polymorphism on the survival of patients
ith heart failure was suggested (89). However, all reported
tudies about multifactorial DCM have methodologic lim-
tations, and results should be considered as preliminary.
his is due to the small size of the populations, and to the
act that some of the studies were retrospective, that results
ere usually not replicated in independent populations, that
ultiple statistical comparisons may produce false-positive
esults, and finally that interactions between polymor-
hisms/genes were not examined. Another important issue
s to clearly describe the functional role of the variants
dentified.
RACTICAL ISSUES FOR THE CLINICIAN
ecause it is now established that familial cases account for
t least 30% of all DCM, it should, therefore, be recom-
ended to perform routine echocardiographic evaluation in
ll first-degree relatives. This evaluation would allow de-
ecting affected relatives, who could benefit from an early
ollow-up and treatment. It could also identify relatives with
c Dilated Cardiomyopathy
Odds Ratio (95% CI) Reference
1.9 (1.3–2.9) (95)
2.30 (1.27–3.33) (96)
3.46 (1.99–4.93) (96)
1.9 (1.2–3.0) (97)
6.25 (1.92–20.3) (98)
p  0.017 (99)
5.65 (2.7–11.9) (100)
5.20 (3.60–8.50) (101)
an leukocyte antigen; PAF  platelet activating factor; TGFgeni
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Genetic Bases of Cardiomyopathies November 7, 2006:A79–89ild depressed systolic function) who could benefit from a
erial echocardiographic follow-up, because these individu-
ls are at risk of developing the disease (90). Although there
s no prospective study in this area, early treatment by
ngiotensin-converting enzyme inhibitors or beta-blockers
ould limit the progression of the disease in these high-risk
atients (91,92). However, unlike HCM, genetic testing
annot be recommended in routine in common forms of
amilial DCM due to the poor yield and the excessive cost
f this strategy. The only exception concerns the MYH7
utations, which could be involved in up to 10% of these
amilies. We propose an analysis of this gene in some
amilies, when genetic results may have clinical implication
n terms of pre-clinical diagnosis. In addition, some associ-
ted phenotypes, such as skeletal myopathy, atrial fibrilla-
ion, or conduction disorders, must be carefully examined as
hey could orient toward specific gene mutations, as for
xample LMNA mutations. In our experience, according to
he high rate of de novo mutations found in LMNA, we
ropose this analysis in all DCM patients (familial and
poradic cases) with conduction disorders (93). This could
ave therapeutic implication because lamin A/C mutations
re associated with a high rate of sudden death (94).
nalysis of genetic factors involved in non-monogenic
orms of DCM (susceptibility or modifier genes) cannot be
ecommended in clinical practice at the present time be-
ause available results are only preliminary and still required
o be confirmed in large independent populations. In the
uture however, these genetic factors will be probably of
reat interest. The characterization of modifier genes in a
atient with multifactorial DCM will be particularly useful
o improve the prognostic stratification and better decide
he therapeutic management of the patient.
LINICAL PERSPECTIVES
ERIVED FROM MOLECULAR RESULTS
oday, more than 40% of patients with familial HCM and
ven more patients with DCM remain with non-identified
ausing gene defects. In addition, several loci with unknown
andidate genes have been identified in patients with DCM.
enetic heterogeneity at both locus and mutation levels
able 4. Modifier Genes in Non-Monogenic Dilated Cardiomyo
Gene Polymorphism
CE Ins/Del 49% vs. 7
eta 2 AR Ile64Thr 42% vs. 7
MPD1 missense mutation 7.6 vs. 3
eta 1 AR Ser49Gly 39% vs. 6
TA receptor H323H OR 5.5 f
OS 3 Glu298Asp p  0.03
MP-3 and -9 5A/5A (3)
T allele (9)
HR 2.92
HR 1.81
EGF 405C/G promoter RR 1.65
Mixed with ischemic cardiomyopathy.
ACE  angiotensin-converting enzyme; AMPD1  adenosine monophosp
etalloproteinase; NOS  nitric oxide synthase; OR  odds ratio; RR  relative reads to time-consuming and expensive genetic analyses thatre not taken in charge by health insurances. The develop-
ent of new sensitive, fast, and cheap technologies for
utation screening could be an important issue in the
iagnosis of these diseases. Genetic heterogeneity also
epresents an important limitation to better understand the
omplex relations between genotype and phenotype in both
CM and DCM. Therefore, there is a need for large
nternational cohorts of patients and relatives with common
henotypic criteria and follow-up procedures, and for DNA
anks. The Eurogene Heart Failure Study, which was
aunched in 2001 with the support of the Fondation
educq, is a large European registry of more than 2,500
atients with HCM and DCM and relatives, included from
1 centers in Europe. This registry will provide in the next
ears important insights regarding the role of genetics in
ardiomyopathies. This includes discovery of new causal
enes, genes of susceptibility, and modifier genes. It is
nticipated that results obtained by this European consor-
ium will translate into a better understanding of the
echanisms of HCM and DCM, and ultimately to better
anagement of these high-risk patients.
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